Harbor Capital Advisors Inc. Lowers Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Harbor Capital Advisors Inc. lessened its position in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 72.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,401 shares of the medical device company's stock after selling 11,301 shares during the period. Harbor Capital Advisors Inc.'s holdings in DexCom were worth $295,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of DexCom in the second quarter worth $25,000. Sachetta LLC lifted its holdings in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company's stock worth $27,000 after buying an additional 171 shares during the period. Crewe Advisors LLC bought a new stake in shares of DexCom in the 1st quarter valued at about $29,000. Riverview Trust Co increased its stake in shares of DexCom by 100.4% in the third quarter. Riverview Trust Co now owns 463 shares of the medical device company's stock valued at $31,000 after buying an additional 232 shares during the period. Finally, DT Investment Partners LLC raised its position in shares of DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company's stock worth $43,000 after acquiring an additional 315 shares during the last quarter. 97.75% of the stock is currently owned by institutional investors.

Insider Activity at DexCom

In other DexCom news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In other DexCom news, EVP Sadie Stern sold 426 shares of DexCom stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the sale, the executive vice president now owns 75,451 shares of the company's stock, valued at $5,217,436.65. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at $18,318,872.25. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 0.30% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the stock. Barclays decreased their target price on shares of DexCom from $138.00 to $113.00 and set an "equal weight" rating for the company in a research report on Monday, July 29th. Canaccord Genuity Group restated a "buy" rating and issued a $145.00 target price on shares of DexCom in a report on Tuesday, July 23rd. Morgan Stanley dropped their price target on DexCom from $120.00 to $75.00 and set an "equal weight" rating on the stock in a research note on Friday, July 26th. Piper Sandler reissued an "overweight" rating and set a $90.00 target price on shares of DexCom in a research note on Monday, August 26th. Finally, Baird R W downgraded shares of DexCom from a "strong-buy" rating to a "hold" rating in a research note on Friday, July 26th. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $104.59.

DexCom Stock Performance

Shares of DexCom stock traded up $1.85 during mid-day trading on Friday, hitting $70.76. 1,573,108 shares of the stock were exchanged, compared to its average volume of 3,900,042. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a 50-day simple moving average of $69.65 and a 200 day simple moving average of $94.12. The company has a market capitalization of $27.64 billion, a P/E ratio of 41.69, a P/E/G ratio of 2.14 and a beta of 1.17. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.12 and a current ratio of 2.46.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.